ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 2441

Investigating Kidney Disease Risks in Systemic Sclerosis (SSc) – Effects of Proton Pump Inhibitors (PPI): Retrospective Analysis
Abstract Number: 2442

Clustering Algorithm as an Exploratory Analysis of Different Clinical Phenotypes in Systemic Sclerosis. Data from the PRECISESADS Study
Abstract Number: 2443

The Clinical Phenotype of Anti-Th/To+ Patients in Systemic Sclerosis: A Case-control Study Within the European Scleroderma Trials and Research (EUSTAR) Cohort
Abstract Number: 2444

Performance of the DETECT Algorithm and Cluster Analysis in Screening for Systemic Sclerosis Pulmonary Hypertension Groups
Abstract Number: 2445

Effects of Aminaphtone on TGF-beta1 Serum Concentration as Concomitant Treatment to Standard Therapy in Systemic Sclerosis Patients: A Pilot Study
Abstract Number: 2446

Nailfold Videocapillaroscopy Findings in Patients with Limited Cutaneous versus Diffuse Cutaneous Systemic Sclerosis: The First Detailed Retrospective Study
Abstract Number: 2447

Features of Anti-Fibrillarin Positive Systemic Sclerosis Patients and Ethnic Differences: A European Multicenter Cohort
Abstract Number: 2448

Content Validity and Sensitivity to Change of ScleroID Through the Natural History of Scleroderma. a Validated Tool to Measure the Impact of SSc on How Patients Feel and Function
Abstract Number: 2449

Acid Reflux Triggers Type I Interferon and Persistent Epithelial-mesenchymal Transition in Esophageal Epithelial Cells. a Novel Microenvironment Contribution to the Pathogenesis of Systemic Sclerosis
Abstract Number: 2450

Disease Progression in Anti-Centromere Positive Systemic Sclerosis Patients
Abstract Number: 2451

Prognostic Value of Functional Outcomes in a Italian Multicentric Cohort of Early SSc-ILD Patients
Abstract Number: 2452

Multimodal Ultrasound in the Assessment of Sarcopenia-related Muscle Involvement in Patients with Systemic Sclerosis: A Multicentric Study
Abstract Number: 2453

Gastrointestinal Symptom Severity and Intestinal Permeability in Systemic Sclerosis: A Single Center Prospective Study
Abstract Number: 2454

Age-Adjusted Mortality Rate Trends in Systemic Sclerosis in the United States from 1999 to 2020
Abstract Number: 2455

Improvement Across Multi-organ Domains and Patient Reported Outcomes in Refractory Juvenile-Onset Systemic Sclerosis (jSSc) up to 4 Years After Autologous Stem Cell Transplantation (ASCT)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].